Literature DB >> 14700242

Regional variation in HIV prevalence and risk behaviours in Ontario injection drug users (IDU).

Peggy Millson1, Ted Myers, Liviana Calzavara, Evelyn Wallace, Carol Major, Naushaba Degani.   

Abstract

OBJECTIVES: To measure HIV prevalence, risk behaviours, and further service needs in needle exchange programs throughout Ontario, and to conduct regional comparisons.
METHODS: Injection drug users (IDU) recruited through the efforts of needle exchange programme (NEP) staff in 9 Ontario cities during 1997-98 completed questionnaires about their drug use and behaviours and provided saliva and/or dried blood samples for anonymous unlinked HIV testing.
RESULTS: Demographic and drug use characteristics of participants showed great regional variation. HIV prevalence by region ranged from 1.4% to 14.7%. In addition to region, HIV positivity was associated with injecting for more than 5 years, use of (powder) cocaine, use of crack, binge injection (10 or more times per day at least once in the previous 6 months), and being a longer-term NEP user. Sharing of injection equipment, and especially of other drug injection materials such as water and cookers, remain important issues, although much of the sharing reported is with only one other person. Unmet demand for methadone treatment was identified despite changes in regulation of methadone provision designed to make it more accessible.
CONCLUSIONS: This study suggested significant further HIV prevention needs among IDU throughout Ontario. There is also evidence of potential to provide additional services such as methadone at NEPs if the required resources are invested. NEPs that have succeeded in gaining the trust of high-risk IDU offer a means to provide access to needed services.

Entities:  

Mesh:

Year:  2003        PMID: 14700242

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  7 in total

1.  Increasing prevalence of cocaine as the primary detoxification diagnosis among admissions presenting with current intravenous drug use: a review of detoxification records from northern British Columbia, 1999-2005.

Authors:  Russell C Callaghan; Carol Strike; Thomas Kerr; Benedikt Fischer; Jane Buxton; Emma Stevens; Lawren Taylor; J Charles Victor
Journal:  Can J Public Health       Date:  2008 May-Jun

Review 2.  Epidemiology of Injection Drug Use: New Trends and Prominent Issues.

Authors:  Élise Roy; Nelson Arruda; Julie Bruneau; Didier Jutras-Aswad
Journal:  Can J Psychiatry       Date:  2016-02-10       Impact factor: 4.356

3.  Strong HIV and hepatitis disclosure norms and frequent risk behaviors among Hungarian drug injectors.

Authors:  V Anna Gyarmathy; Alan Neaigus; Eszter Ujhelyi; Tímea Szabó; József Rácz
Journal:  Drug Alcohol Depend       Date:  2006-04       Impact factor: 4.492

4.  Injecting equipment sharing and perception of HIV and hepatitis risk among injecting drug users in Budapest.

Authors:  J Rácz; V A Gyarmathy; A Neaigus; E Ujhelyi
Journal:  AIDS Care       Date:  2007-01

5.  Not all injection drug users are created equal: heterogeneity of HIV, hepatitis C virus, and hepatitis B virus infection in Georgia.

Authors:  Mark H Kuniholm; Malvina Aladashvili; Carlos Del Rio; Ketavan Stvilia; Nino Gabelia; Rohit A Chitale; Tengiz Tsertsvadze; Kenrad E Nelson
Journal:  Subst Use Misuse       Date:  2008       Impact factor: 2.164

6.  Social determinants of health associated with hepatitis C co-infection among people living with HIV: results from the Positive Spaces, Healthy Places study.

Authors:  Sean B Rourke; Michael Sobota; Ruthann Tucker; Tsegaye Bekele; Katherine Gibson; Saara Greene; Colleen Price; J J Jay Koornstra; Laverne Monette; Steve Byers; James Watson; Stephen W Hwang; Dale Guenter; James Dunn; Amrita Ahluwalia; Michael G Wilson; Jean Bacon
Journal:  Open Med       Date:  2011-07-05

7.  Outlier populations: individual and social network correlates of solvent-using injection drug users.

Authors:  Souradet Y Shaw; Ann M Jolly; John L Wylie
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.